BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent

Famicord, Europe’s Largest Cord Blood Bank, and India’s CelluGen, Sign Letter of Intent

May 6, 2019 By Cade Hildreth (CEO) Leave a Comment

FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs.

Discover class-defining bioproduction tools.

European Cord Blood Consolidation

This announcement by Famicord is the continuation of an ongoing trend within the European cord blood market, as well as the global cord blood market. After a rapid growth period through the mid-2000s, the global cord blood banking market reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating, both in Europe and worldwide.

Thus far, FamiCord Group has completed more than a dozen M& deals within the European market. Vita34 and Esperite (CryoSave Group) have each completed 5-10 each acquisition deals. StemLab also did at least three M&A deals prior to being acquired by PBKM (FamiCord Group).

As a result of this flurry of M&A activity, most cord blood industry growth within Europe is inorganic. The number of cord blood banks in Europe also dropped from over 150 at its peak to less than 100 today. The three largest cord blood banks in Europe are the ones that have been executing consistent M&A activity: FamiCord Group, Vita34, and Esperite (CryoSave Group), respectively.

Rooster DevServices

Additionally, Famicord (PBKM) announced in February of 2019 that it may acquire Esperite NV’s (Cryo-Save) stem cell banking business. While this transaction has not yet been completed, Cryo-Save has been having financial struggles. Under these circumstances, the deal will likely be confirmed.

FamiCord as a Leading Stem Cell Bank

Famicord represents an important competitor within the global cord blood banking marketplace. As stated by the company, it is now the fifth largest stem cell bank in the world.

bitbio

Other FamiCord® Group facts and figures include:

  • Storage of 280,000+ cord blood and tissue units
  • 59 cord blood transplantations (26 in Poland, 4 in Hungary, 15 in Turkey, 1 in Jordan, 10 in USA, 2 in Spain, 1 in Portugal)
  • 10 laboratory facilities: Poland (2), Hungary, Romania, Spain (2), Turkey, Switzerland (2), Portugal
  • 2,100+ patients treated with mesenchymal stem cells (MSCs)
  • Cooperation with 1300+ hospitals across Europe

Famicord and CelluGen Biotech

With regard to the recent LOI signed by Famicord and Cellugen Biotech, Jakub Baran, Co-founder and Shareholder of FamiCord Group states:

“We have decided to start cooperation with CelluGen because it can generate beneficial synergies for both companies in the field of family-based stem cell banking and the development of new stem cell-based drugs. Cooperation with CelluGen may also be a potential opportunity for the FamiCord Group to enter a new market outside Europe depending on the development of our cooperation; we do not rule out that in the future the next step may be capital involvement.”

Pluristyx

To learn more about the cord blood banking market, view the “Global Cord Blood Banking Industry Report.”

Do you have questions about this partnership between Famicord and CelluGen? Ask them in the comments below.

4.6/5 - (8 votes)

Filed Under: Cord Blood, Stem Cell News Tagged With: cord blood, Famicord, M&A

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Featured Posts

clean meat market

Clean Meat Market: Stem Cell Derived “Clean Meat” Attracts Billionaires

what are exosomes | definition

What are Exosomes, Exactly?

Who discovered stem cells?

Who Discovered Stem Cells? The Answers Revealed

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.